Platinum-based chemotherapy inflames the ovarian carcinoma microenvironment through cellular senescence.
BRCA1/2
CGAS
GEMM
NK cells
PD-1
senescence-associated secretory phenotype
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
21
3
2022
pubmed:
22
3
2022
medline:
9
4
2022
Statut:
epublish
Résumé
Epithelial ovarian carcinoma (EOC) is virtually insensitive to immune checkpoint inhibitors (ICIs). Recent findings from an innovative mouse model of EOC demonstrate that senescence induction underlies the increased sensitivity of homologous recombination-defective EOCs to platinum-based chemotherapy as it initiates tumor infiltration by immune effector cells coupled to restored sensitivity to ICIs.
Identifiants
pubmed: 35309729
doi: 10.1080/2162402X.2022.2052411
pii: 2052411
pmc: PMC8932912
doi:
Substances chimiques
Platinum
49DFR088MY
Types de publication
Editorial
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
2052411Informations de copyright
© 2022 Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
EGM has been holding research contracts with Roche, has received consulting/advisory honoraria from AstraZeneca, GSK, Clovis, as well as financial support for attending symposia from Roche, AstraZeneca, Pfizer, and MSD. LG has been holding research contracts with Lytix Biopharma and Phosplatin, and has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Volastra, and the Luke Heller TECPR2 Foundation. BAA has no conflicts to declare.
Références
Cancer Res. 2021 Oct 15;81(20):5147-5160
pubmed: 34301761
Oncotarget. 2016 Mar 22;7(12):13587-98
pubmed: 26871470
Cell. 2019 Oct 31;179(4):813-827
pubmed: 31675495
Cell Rep Med. 2020 May 19;1(2):100020
pubmed: 33205059
Int J Mol Sci. 2019 Feb 22;20(4):
pubmed: 30813239
Sci Transl Med. 2018 Sep 19;10(459):
pubmed: 30232229
Nat Immunol. 2020 Oct;21(10):1160-1171
pubmed: 32747819
Trends Cancer. 2022 Feb 15;:
pubmed: 35181272
Cell Rep. 2018 Dec 11;25(11):2972-2980.e5
pubmed: 30540933
Proc Natl Acad Sci U S A. 2022 Feb 1;119(5):
pubmed: 35082152